ACADIA Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-07-16
- Employees
- 598
- Market Cap
- $2.6B
- Website
- http://www.acadia.com
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2012-01-26
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT01518309
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 199
- Registration Number
- NCT01174004
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-04-15
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT00658567
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-29
- Last Posted Date
- 2019-06-24
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 459
- Registration Number
- NCT00550238
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
- First Posted Date
- 2007-06-22
- Last Posted Date
- 2017-04-20
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 247
- Registration Number
- NCT00490516
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-05-17
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 298
- Registration Number
- NCT00477672
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-08-07
- Last Posted Date
- 2007-03-22
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT00361166
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-07-14
- Last Posted Date
- 2005-12-07
- Lead Sponsor
- ACADIA Pharmaceuticals Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT00087542
© Copyright 2024. All Rights Reserved by MedPath